BETA

4 Amendments of Angélique DELAHAYE related to 2016/2057(INI)

Amendment 179 #
Motion for a resolution
Paragraph 2 a (new)
2a. Criticises the fact that health expenses continue to be seen only as a cost and not as an investment, and that medicine is always the first variable in economic measures in our healthcare systems;
2016/10/21
Committee: ENVI
Amendment 281 #
Motion for a resolution
Paragraph 10 a (new)
10a. points out that competence for pricing and reimbursement decisions falls exclusively to Member States;
2016/10/21
Committee: ENVI
Amendment 447 #
Motion for a resolution
Paragraph 22
22. Calls on the Commission to review the regulatory framework for orphan medicines, to define clearly the concept of unmet medical needs, to assess the impact of incentives to develop effective, safe and affordable drugs comparHighlights the success of Regulation (EC) No 141/2000 on orphan medicinal products, which enabled a number of innovative products for misdiagnosed patients or patients deprived of treatment to be placed ton the best available alternative andmarket; calls on the Commission to promote the European register of rare diseases and reference centres;
2016/10/21
Committee: ENVI
Amendment 500 #
Motion for a resolution
Paragraph 25
25. Calls on the Commission to propose legislation on a European system for health technology assessment as soon as possible, and to assessWelcomes the HTA multi-annual work programme 2016-2020 and recognises the added- value medicines compared with the best available alternative; also calls on the Commission to harmonise pricing and reimbursement criteria to take into account the level of innovation and the social and economic cost-benefit analysis, and to put in place a European classificof European cooperation when it comes to assessing health technology; calls on the Commission to propose legislation on establishing a system for health technology assessment as soon as possible; calls for that system to be developed in close collaboration onwith the added value level of medicines;European Medicines Agency.
2016/10/21
Committee: ENVI